A Prospective, Multinational, Open-Label, Single-Arm, Explorative Study To Evaluate The Tolerability And Efficacy Of Lacosamide When Added To Levetiracetam With Withdrawal Of The Concomitant Sodium Channel Blocking Antiepileptic Drug In Subjects With Uncontrolled Partial-Onset Seizures.

Trial Profile

A Prospective, Multinational, Open-Label, Single-Arm, Explorative Study To Evaluate The Tolerability And Efficacy Of Lacosamide When Added To Levetiracetam With Withdrawal Of The Concomitant Sodium Channel Blocking Antiepileptic Drug In Subjects With Uncontrolled Partial-Onset Seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Lacosamide (Primary) ; Levetiracetam
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms OCToPOS; VERVE
  • Sponsors UCB
  • Most Recent Events

    • 24 May 2017 Planned locations also included Austria, Canada, Hungary, Netherlands, Switzerland.
    • 01 Apr 2017 Results assessing efficacy and of post hoc analysis (n=51) assessing effectiveness of LCM among patients treated within dose range (less than or equal to 400 Mg/ Day), published in the Acta Neurologica Scandinavica
    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top